Pharmaceuticals 2013, 6(8), 915-928; doi:10.3390/ph6080915
Review

Targeting Platelet Thrombin Receptor Signaling to Prevent Thrombosis

1 Division of Cardiovascular Medicine and the Gill Heart Institute, University of Kentucky, Lexington, KY 40536, USA 2 Lexington VA Medical Center, Lexington, KY 40536, USA
* Author to whom correspondence should be addressed.
Received: 6 May 2013; in revised form: 18 July 2013 / Accepted: 26 July 2013 / Published: 2 August 2013
(This article belongs to the Special Issue GPCR Based Drug Discovery)
PDF Full-text Download PDF Full-Text [249 KB, uploaded 2 August 2013 08:29 CEST]
Abstract: Platelets contribute fundamentally to ischemic heart disease, and antiplatelet therapy has been critical to reducing acute thrombotic complications of atherosclerotic disease. Thrombin, by acting on protease activated receptors (PAR), is one of the most potent platelet activators. PAR-1 antagonists may therefore provide more comprehensive antithrombotic effects. We review the pathophysiology of atherothrombosis, platelet activation by thrombin, the role of platelet protease activated receptors (PAR), and the clinical data supporting their use.
Keywords: platelets; thrombin; thrombosis; protease-activated receptors

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Wallace, E.L.; Smyth, S.S. Targeting Platelet Thrombin Receptor Signaling to Prevent Thrombosis. Pharmaceuticals 2013, 6, 915-928.

AMA Style

Wallace EL, Smyth SS. Targeting Platelet Thrombin Receptor Signaling to Prevent Thrombosis. Pharmaceuticals. 2013; 6(8):915-928.

Chicago/Turabian Style

Wallace, Eric L.; Smyth, Susan S. 2013. "Targeting Platelet Thrombin Receptor Signaling to Prevent Thrombosis." Pharmaceuticals 6, no. 8: 915-928.

Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert